Journal article

Acute Intraocular Inflammation after Intravitreous Injections of Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Sanjeewa S Wickremasinghe, Kira Michalova, Jagjit Gilhotra, Robyn H Guymer, C Alex Harper, Tien Y Wong, Salmaan Qureshi

OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2008

Abstract

PURPOSE: Bevacizumab is an inhibitor of vascular endothelial growth factor widely used as an "off-label" treatment of neovascular age-related macular degeneration (AMD), despite the lack of clinical trial data on efficacy or safety of this drug. We describe acute intraocular inflammation after intravitreous injection of bevacizumab for the treatment of neovascular AMD. DESIGN: A retrospective case series. PARTICIPANTS: Patients with neovascular AMD treated with intravitreous injection of bevacizumab from clinical practices in 2 states (Victoria and South Australia) in Australia. METHODS: We retrospectively reviewed cases of acute intraocular inflammation after intravitreous injection of beva..

View full abstract